GlassScriptPhysician profile
Abdul Nadir
NPI 1780752907
$12,403.71
in general payments reported to CMS, 2019-2025
33 companies · $2,878 in 2025
The $2,878 reported for 2025 was more than what 86% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $337 · 2020: $97.84 · 2021: $105 · 2022: $2,161 · 2023: $1,910 · 2024: $4,915 · 2025: $2,878.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,881 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,115 · Travel and Lodging: $875 · Consulting Fee: $698 · Education: $135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,881.01 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,115.00 |
| Travel and Lodging | $875.01 |
| Consulting Fee | $697.50 |
| Education | $134.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $2,667.99 | 2024-2025 | Rezdiffra, Resmetirom |
| Boston Scientific Corporation | $2,517.33 | 2021-2025 | Resolution 360 Ultra Clip, General - Hemostasis, Axios |
| Abbvie INC. | $869.03 | 2019-2025 | |
| Janssen Biotech, INC. | $826.59 | 2024-2025 | Tremfya, Stelara |
| Gilead Sciences, INC. | $762.86 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $697.50 | 2025 | |
| Enterra Medical, INC. | $697.30 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $459.26 | 2022-2023 | Xifaxan, Trulance |
| Ipsen Biopharmaceuticals, INC | $406.05 | 2024-2025 | Iqirvo, Bylvay |
| E.R. Squibb & Sons, L.L.C. | $333.61 | 2022-2023 | Zeposia |
| Exact Sciences Corporation | $301.76 | 2023 | |
| Nestle Healthcare Nutrition INC. | $203.59 | 2023 | |
| Phathom Pharmaceuticals, INC. | $183.96 | 2024 | Voquezna |
| Pharmacosmos Therapeutics INC. | $169.35 | 2023 | Monoferric |
| Lilly USA, LLC | $155.78 | 2024 | Omvoh |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $150.14 | 2023 | Terlivaz |
| Dynavax Technologies Corporation | $115.59 | 2022 | |
| Tempus Ai, INC | $115.29 | 2025 | Xt Cdx |
| W. L. Gore & Associates, INC. | $114.69 | 2022-2023 | Gore Cardioform Septal Occluder |
| Regeneron Healthcare Solutions, INC. | $104.86 | 2024-2025 | Dupixent |
| Janssen Scientific Affairs, LLC | $101.21 | 2025 | Tremfya |
| Intercept Pharmaceuticals, INC. | $88.64 | 2020-2022 | |
| Medtronic, INC. | $75.60 | 2023-2024 | Gi Genius, Bravo |
| Davol INC. | $56.52 | 2023 | Phasix Mesh |
| Shionogi INC | $40.71 | 2019 | |
| Celgene Corporation | $36.91 | 2023-2024 | Zeposia |
| Digestive Care, INC. | $33.97 | 2023 | Pertzye |
| Qol Medical, LLC | $31.41 | 2019 | |
| Ucb, INC. | $20.53 | 2019 | |
| Capsovision, INC. | $19.71 | 2023 | Capsocam Plus |
| Urgo Medical North America, LLC | $18.03 | 2024 | Vashe Wound Solution 250 Ml (8.5 Fl Oz) Flip Top Cap |
| Ferring Pharmaceuticals INC. | $15.27 | 2023 | Rebyota |
| Northgate Technologies, INC. | $12.67 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abdul Nadir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.